References
- Whitehead MI. The effects of oestrogens and progestogens on the postmenopausal endometrium. Maturitas 1978;1:87–98.
- Voigt LF, Weiss NS, Chu J, Daling JR, McKnight B, van Belle G. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 1991;338:274–277.
- Schiff I, Sela HK, Cramer D, Tulchinsky D, Ryan KJ. Endometrial hyperplasia in women on cyclic or continuous estrogen regimens. Fertil Steril 1982;37:79–82.
- Harlap S. The benefits and risks of hormone replacement therapy: an epidemiologic overview. Am J Obstet Gynecol 1992;166:1986–1992.
- Whitehead MI. Prevention of endometrial abnormalities. Acta Obstet Gynecol Scand Suppl 1986;134:81–91.
- Woodruff JD, Pickar JH. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Pre-marin) with medroxyprogesterone acetate or conjugated estrogens alone. Am J Obstet Gynecol 1994;170:1213–1223.
- Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmeno-pausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1996;275:370–375.
- Philibert D, Bouchoux F, Degryse M, Lecaque D, Petit F, Gaillard M. The pharmacological profile of a novel norpreg-nane progestin (trimegestone). Gynecol Endocrinol 1999;13: 316–326.
- Winneker RC, Bitran D, Zhang Z. The preclinical biology of a new potent and selective progestin: trimegestone. Steroids 2003;68:915–920.
- Al-Azzawi F, Wahab M, Thompson J, Pornel B, Hirvonen E, Ylikorkala 0, van der Mooren MJ, Dillon J, Magaril C. Acceptability and patterns of endometrial bleeding in estra-diol-based HRT regimens: a comparative study of cyclical sequential combinations of trimegestone or norethisterone acetate. Climacteric 2001;4: 343–354.
- Archer DF, Fischer LA, Rich D, Schade GH, Schwartz S, Wittcoff H, Clark CS Sr, Maloney K, Smith FO. Estrace® vs Premarin® for treatment of menopausal symptoms: dosage comparison study. Adv Ther 1992;9:21–31.
- Notelovitz M, Lenihan JP Jr, McDermott M, Kerber IJ, Nanavati N, Arce J-C. Initial 17#-estradiol dose for treating vasomotor symptoms. Obstet Gynecol 2000;95: 726–731.
- Stadberg E, Mattsson L-A, Uvebrant M. 17#-Estradiol and norethisterone acetate in low doses as continuous combined hormone replacement therapy. Maturitas 1996;23: 31–39.
- Gordon SF, Thompson KA, Ruoff GE, Imig JR, Lane PJ, Schwenker CE, Transdermal Estradiol Patch Study Group. Efficacy and safety of a seven-day, transdermal estradiol drug-delivery system: comparison with conjugated estrogens and placebo. Int J Fertil 1995;40:126–134.
- Al-Azzawi F, Wahab M, Thompson J, Whitehead M, Thompson W. Acceptability and patterns of uterine bleeding in sequential trimegestone-based hormone replacement ther-apy: a dose-ranging study. Hum Reprod 1999;14:636–641.
- Koninckx P, Spielmann D, Trimegestone 302 Study Group. A comparative 2-year study of the effects of sequential regimens of 1 mg 17/3-estradiol and trimegestone with a regimen containing estradiol valerate and norethisterone upon the bleeding profile and endometrial safety in postmenopausal women. Gynecol Endocrinol 2005;21(2):82–89.
- Kupperman HS, Blatt MHG, Wiesbader H, Filler W. Comparative clinical evaluation of estrogenic preparations by the menopausal and amenorrheal indices. J Chin Endocrinol Metab 1953;13:688–703.
- Hunter M. The Women's Health Questionnaire: a measure of mid-aged women's perceptions of their emotional and physical health. Psychol Health 1992;7:45–54.
- Committee for Proprietary Medicinal Products. Points to consider on switching between superiority and non-inferiority. London: European Agency for the Evaluation of Medicinal Products; 2000.
- Derman RJ, Dawood MY, Stone S. Quality of life during sequential hormone replacement therapy — a placebo-con-trolled study. hit J Fertil 1995;40:73–78.
- Baerug U, Winge T, Nordland G, Faber-Swensson E, Heldaas K, Norling B, Larsen S, Arce J-C. Do combinations of 1 mg estradiol and low doses of NETA effectively control menopausal symptoms? Climacteric 1998;1: 219–228.
- Gambacciani M, Ciaponi M, Cappagli B, Monteleone P, Benussi C, Bevilacqua G, Genazzani AR. Effects of low-dose, continuous combined estradiol and norethisterone acetate on menopausal quality of life in early postmenopausal women. Maturitas 2003;44:157–163.
- Bech P, Munk-Jensen N, Obel EB, Ulrich LG, Eiken P, Nielsen SP. Combined versus sequential hormonal replace-ment therapy: a double-blind, placebo-controlled study on quality of life-related outcome measures. Psychother Psycho-som 1998;67:259–265.